Annexon

Annexon is developing novel therapeutics for neurodegenerative and autoimmune disorders. We have discovered that early components of the classical complement cascade accumulate on synapses with normal aging and are activated as the brain encounters stress or disease to cause loss of nerve connections. Annexon’s most advanced program targets Huntington’s disease.

Focus area
Neuroscience
Graduation date
07/29/2017
Commencement date
04/22/2015